Agnes E. Hamburger
Research Subjects
Research Interests
Agnes E. Hamburger has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kamb
A2 Biotherapeutics Inc, Agoura Hills, California, USA
3 shared publications Jee-Young Mock
A2 Biotherapeutics, 30301 Agoura Road, Agoura Hills, CA 91301, USA
3 shared publications- Talar Tokatlian
A2 Biotherapeutics, Agoura Hills, CA, USA
3 shared publications - Aaron D. Martin
A2 Biotherapeutics, 30301 Agoura Rd., Agoura Hills, CA, 91301, United States
2 shared publications Grace E. Asuelime
Research, A2 Biotherapeutics, Agoura Hills, California
2 shared publicationsMark E. Daris
Research, A2 Biotherapeutics, Agoura Hills, California
2 shared publications
Latest Publications
- Open Access
- 4 October 2022
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 27, 157-166
HLA-A∗02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen
- 4 October 2022
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 27, 157-166
Open AccessHLA-A∗02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen
- Open Access
- 28 January 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 2 (1) , 58-65
Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity
Neoantigens are among the most intriguing potential immuno-oncology targets because, unlike many cancer targets that are expressed on normal tissues, they are by definition restricted to cancer cells. Medicines directed at common neoantigens such as mutant KRAS are especially interesting because they may offer the convenience and cost of an off-the-shelf therapy. However, all common KRAS mutations produce proteins that differ from the wild type at a single amino acid, creating challenges for molecular discrimination. We have undertaken an effort to optimize single-chain variable fragments (scFv) against peptide/major histocompatibility antigen complexes composed of HLA-A*11 and either G12V- or G12D-mutant KRAS peptides. These scFvs could in principle be used in chimeric antigen receptor (CAR) T-cell therapies for selected patients whose tumors bear either of these mutations. Here we show that optimization of such CARs involves a trade-off between potency and selectivity. We further show that targeting this family without high selectivity engenders risks of cross-reactivity against other members of the G-protein family to which KRAS belongs.Significance: We report an effort to generate high potency, selective CARs directed at mutant KRAS peptides. Although the heavily optimized CARs maintain high selectivity against wild-type KRAS, they lose selectivity against other KRAS-related peptides derived from human proteins. To our knowledge, this work is the first to examine the trade-off between potency and selectivity with regard to KRAS pMHC-directed CARs, illustrating the challenge to achieve both sufficient potency and high selectivity.
- 28 January 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 2 (1) , 58-65
Open AccessChimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity
Neoantigens are among the most intriguing potential immuno-oncology targets because, unlike many cancer targets that are expressed on normal tissues, they are by definition restricted to cancer cells. Medicines directed at common neoantigens such as mutant KRAS are especially interesting because they may offer the convenience and cost of an off-the-shelf therapy. However, all common KRAS mutations produce proteins that differ from the wild type at a single amino acid, creating challenges for molecular discrimination. We have undertaken an effort to optimize single-chain variable fragments (scFv) against peptide/major histocompatibility antigen complexes composed of HLA-A*11 and either G12V- or G12D-mutant KRAS peptides. These scFvs could in principle be used in chimeric antigen receptor (CAR) T-cell therapies for selected patients whose tumors bear either of these mutations. Here we show that optimization of such CARs involves a trade-off between potency and selectivity. We further show that targeting this family without high selectivity engenders risks of cross-reactivity against other members of the G-protein family to which KRAS belongs.Significance: We report an effort to generate high potency, selective CARs directed at mutant KRAS peptides. Although the heavily optimized CARs maintain high selectivity against wild-type KRAS, they lose selectivity against other KRAS-related peptides derived from human proteins. To our knowledge, this work is the first to examine the trade-off between potency and selectivity with regard to KRAS pMHC-directed CARs, illustrating the challenge to achieve both sufficient potency and high selectivity.
- Open Access
- 1 December 2020
- Published by Elsevier in Molecular Immunology
- Vol. 128, 298-310
Engineered T cells directed at tumors with defined allelic loss
- 1 December 2020
- Published by Elsevier in Molecular Immunology
- Vol. 128, 298-310
Open AccessEngineered T cells directed at tumors with defined allelic loss
- 1 October 2020
- Published by Elsevier in Molecular Immunology
- Vol. 126, 56-64
Structure-function relationships of chimeric antigen receptors in acute T cell responses to antigen
- 1 October 2020
- Published by Elsevier in Molecular Immunology
- Vol. 126, 56-64
Structure-function relationships of chimeric antigen receptors in acute T cell responses to antigen